Investor Brief · 2026 H1

Neuralink, in brief.

Clinical-stage brain interface building a neural-data moat

Page 1 of 7 · The thesis

Neuralink is a pre-revenue brain-implant company with real clinical progress, and its long-term bull case rests on an unproven neural-data flywheel.

Neuralink is clinical-stage and pre-revenue, so any valuation rests entirely on future expectations.
The hardware works today: 20 surgeries, 27 or more participants, and a stated zero serious device-related adverse events.
The biggest bull case is a data-network flywheel the company has not announced and that may never be permitted at scale.
Weigh exciting medical optionality against long timelines, heavy regulation, and limited financial disclosure.

27+

Participants enrolled

Across the PRIME family of trials by the two-year mark, January 28, 2026 (Neuralink, Two Years of Telepathy).

Implant surgeries to date

With a stated record of zero serious device-related adverse events across all 20 procedures (Neuralink).

1,024 electrodes / 64 threads

Channels per N1 implant

16 electrodes per polymer thread, each thread thinner than a human hair; electrode count is planned to roughly triple (Neuralink).

$650M Series E

Last round (reported)

Closed June 2025 at a reported roughly $9 billion pre-money valuation; valuation figures appear only in news media, so treat as reported, not confirmed (Neuralink, on the round; valuation reported).

Countries with trials

United States, Canada, United Kingdom, and United Arab Emirates, via PRIME, CAN-PRIME, GB-PRIME, and UAE-PRIME (ClinicalTrials.gov).

Up to 40 wpm typing, cursor above 10 BPS

Top decoding performance

One participant exceeded an able-bodied mouse benchmark of about 10 bits per second (Neuralink).

The snapshot above is the free preview. The full seven-page brief continues below.

The full brief

Read all seven pages

Page one is free. The next six go deeper: what it is, how the money works (with sourced data charts), the bull and bear cases, what to watch, and the bottom line.

2A brain implant that turns thought into controlWhat it is
3No revenue today, pure optionality on tomorrowHow the money works
4Verified traction plus a possible data flywheelThe bull case
5Pre-revenue reality and unresolved hurdlesThe bear case
6The signposts that would confirm or break the thesisWhat to watch
7Exciting optionality against a pre-revenue realityThe bottom line

All seven briefs for $79, a saving of $40 versus $17 each.

One-time payment · secure checkout by Stripe · instant access on this device. Educational brief, not investment advice.

This is an educational brief, not investment advice and not a recommendation to buy or sell any security. Figures trace to primary filings, official statements, and Grokipedia; privately held valuations are labeled as reported or estimated.